AbbVie Inc. $ABBV Stock Acquired by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 10.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 132,821 shares of the company’s stock after buying an additional 12,862 shares during the period. Farther Finance Advisors LLC’s holdings in AbbVie were worth $34,745,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ACT Advisors LLC. grew its stake in AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC lifted its stake in AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after purchasing an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC lifted its stake in AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares in the last quarter. Fielder Capital Group LLC boosted its holdings in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after purchasing an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC boosted its holdings in shares of AbbVie by 0.4% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after purchasing an additional 43 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations bolster oncology prospects. AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400), a c-Met-directed antibody-drug conjugate, received two FDA Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory review while supporting the value of AbbVie’s growing ADC portfolio. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data adds another potential growth driver. AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result could expand Epkinly’s commercial opportunity if confirmed and approved. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Analysts raised their valuation estimates. JPMorgan increased its AbbVie price target to $300 from $285 and maintained an “overweight” rating. Cantor Fitzgerald also raised its target to $290 from $285 and assigned an “overweight” rating, signaling continued confidence in the company’s pipeline and earnings outlook.
• Neutral Sentiment: Recent operating momentum provides support: AbbVie’s latest reported revenue rose 10.2% year over year to $16.99 billion, while EPS exceeded consensus estimates. However, the stock’s elevated valuation—approximately 77 times earnings—leaves less room for disappointment.
• Negative Sentiment: Dividend sustainability remains a risk. Commentary highlighted a reported payout ratio above 190%, meaning dividends substantially exceed GAAP earnings. Although noncash items and adjusted earnings can distort this measure, investors may remain concerned about long-term dividend coverage and financial flexibility.

AbbVie Trading Up 0.3%

AbbVie stock traded up $0.84 during mid-day trading on Thursday, hitting $272.20. The company’s stock had a trading volume of 5,492,274 shares, compared to its average volume of 6,424,160. The stock’s fifty day moving average is $258.27 and its two-hundred day moving average is $235.87. The firm has a market capitalization of $480.92 billion, a PE ratio of 76.89, a price-to-earnings-growth ratio of 1.22 and a beta of 0.24. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $274.94.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on ABBV shares. Morgan Stanley increased their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Barclays raised their target price on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Argus lifted their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Guggenheim boosted their price target on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their price objective for the company from $235.00 to $300.00 in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $276.64.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.